Revised Myeloproliferative Neoplasms Working Group Consensus Recommendations for Diagnosis and Management of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia

Abstract

Myeloproliferative neoplasms (MPNs) are clonal disorders, derived from abnormal hematopoietic stem cells and result in an excessive production of blood cells. This MPN group of conditions encompasses different diseases with overlapping clinical and biologic similarities. The majority of the conventional therapies of MPN are palliative in nature. However, with the discovery of Janus Kinase 2 (JAK2) mutation and development of targeted JAK1/2 inhibition therapy, the therapeutic options in treatment landscape have changed dramatically. This article presents the revised Indian MPNs Working Group consensus recommendations. It highlights and brings into attention about the recent findings that have defined the state of the art of the diagnosis and therapy in the MPN area, including identification of the new driver and prognostic mutations, treatment goals in the management of myelofibrosis and polycythemia vera (PV), role of the recently approved, targeted tyrosine kinase inhibitor ruxolitinib in PV, and special issues such MPN consideration in patients with splenic vein thrombosis and the management of the disease in pregnancy.

Keywords

Essential thrombocythemia Janus kinase - myelofibrosis - myeloproliferative neoplasm - polycythemia vera

Publication History

Article published online:
17 June 2021

• References

• 1 Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008; 112: 2190-8
• 2 Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem 2012; 19: 4399-413
• 3 Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-405
• 4 Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy. Am J Hematol 2008; 83: 491-7
• 5 Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: Actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 1991; 85: 124-7
• 6 Visser O, Trama A, Maynadié M, Stiller C, Marcos-Gragera R, De Angelis R. et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012; 48: 3257-66
• 7 Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma 2014; 55: 595-600
• 8 Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol 2014; 92: 289-97
• 9 Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355: 2452-66
• 10 Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT. et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 2005; 366: 1945-53
• 11 Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A. et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: An international study of 797 patients. Leukemia 2014; 28: 1804-10
• 12 Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C. et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: An international study of 570 patients. Leukemia 2014; 28: 1494-500
• 13 Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J. et al. Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian J Med Paediatr Oncol 2015; 36: 3-16
• 14 James C, Delhommeau F, Marzac C, Teyssandier I, Couédic JP, Giraudier S. et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006; 20: 350-3
• 15 Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leuk 2007; 21: 1960-3
• 16 Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M. et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. J Clin Oncol 2011; 29: 3179-84
• 17 Gong JZ, Cook JR, Greiner TC, Hedvat C, Hill CE, Lim MS. et al. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: A report of the Association for Molecular Pathology. J Mol Diagn 2013; 15: 733-44
• 18 Mesa RA. The evolving treatment paradigm in myelofibrosis. Leuk Lymphoma 2013; 54: 242-51
• 19 Andersen CL, Andreasson B, Hasselbalch H, Hultcrantz M, Knutsen H, Lindgren M. et al. Nordic Guidelines On the Diagnosis and Treatment of Patients With Myeloproliferative Neoplasms. Available from: http://www.nmpnorg/indexphp/guidelines/1-nmpn-guidelines-2013/file2013. [Last accessed on 2017 Oct 17].
• 20 Cervantes F. How I treat myelofibrosis. Blood 2014; 124: 2635-42
• 21 Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E. et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-901
• 22 Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S. et al. DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-7
• 23 Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A. et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-8
• 24 Abelsson J, Merup M, Birgegård G, WeisBjerrum O, Brinch L, Brune M. et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant 2012; 47: 380-6
• 25 Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009; 83: 154-5
• 26 Al-Ali HK, Stalbovskaya V, Gopalakrishna P. Ruxolitinib overcomes the adverse prognostic effect of anemia in patients with myelofibrosis. (abstract 4583). Blood 2014; 124: 4583
• 27 Cervantes F, Hernández-Boluda JC, Alvarez A, Nadal E, Montserrat E. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica 2000; 85: 595-9
• 28 Mesa RA, Tefferi A. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs 2009; 14: 471-9
• 29 Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH. et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534-41
• 30 Löfvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 1988; 41: 375-81
• 31 Manoharan A. Management of myelofibrosis with intermittent hydroxyurea. Br J Haematol 1991; 77: 252-4
• 32 Martínez-Trillos A, Gaya A, Maffioli M, Arellano-Rodrigo E, Calvo X, Díaz-Beyá M. et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: Results in 40 patients. Ann Hematol 2010; 89: 1233-7
• 33 Jakavi. Package Insert. Mumbai, India: Novartis India Limited; 20 December 2016
• 34 Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L. et al. Long-term efficacy and safety in COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for the treatment of myelofibrosis: 5-year final study results. Leukemia 2016; 30: 1701-7
• 35 Kvasnicka HM, Thiele J, Bueso-Ramos CE, Sun W, Naim A, Sivaraman S. et al. Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study. Poster 1949. Presented at the American Society of Hematology Annual Meeting; 2016.
• 36 Verstovsek S, Gupta V, Gotlib JR, Mesa RA, Vannucchi AM, Kiladjian JJ. et al. A Pooled Overall Survival Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis. Poster 1949. Presented at the American Society of Hematology Annual Meeting; 2016
• 37 Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Ivana G. et al. Myeloproliferative Neoplasms. National Comprehensive Cancer Network. Version I.2017; 2016.
• 38 Latagliata R, Di Veroli A, Palumbo GA, Bonifacio M, Andriani A, Polverelli N. et al. Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis. Abstract 4251. Presented at the American Society of Hematology Annual Meeting; 2016.
• 39 Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G. et al. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: Consensus statements from European Leukemia Net (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia 2015; 29: 20-6
• 40 Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM. et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Leukemia Net (ELN) consensus report. Blood 2013; 122: 1395-8
• 41 Marchioli R, Finazzi G, Specchia G, Masciulli A, Mennitto MR, Barbui T. et al. The CYTO-PV: A large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis 2011; 2011: 794240
• 42 Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rethinking the diagnostic criteria of polycythemia vera. Leukemia 2014; 28: 1191-5
• 43 Griesshammer M, Gisslinger H, Mesa R. Current and future treatment options for polycythemia vera. Ann Hematol 2015; 94: 901-10
• 44 Tibes R, Mesa RA. Emerging drugs for polycythemia vera. Expert Opin Emerg Drugs 2013; 18: 393-404
• 45 Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C. et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114-24
• 46 Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H. et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: Results of a European Leukemia Net (ELN) consensus process. Br J Haematol 2010; 148: 961-3
• 47 Barbui T, Finazzi MC, Finazzi G. Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev 2012; 26: 205-11
• 48 Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F. et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica 2016; 101: 821-9
• 49 Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T. et al. Ruxolitinib proves superior to best available therapy in patients with polycythemia vera (PV) and a nonpalpable spleen: Results from the phase IIIb RESPONSE-2 study. Abstract Release date EHA Learning Center; May 19, 2016; Passamonti F. Label: Abstracts 2016; 10 Jun, 2016. p. 135145.
• 50 Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ. et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 358-67
• 51 Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M. et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215-32
• 52 Budde U, Schaefer G, Mueller N, Egli H, Dent J, Ruggeri Z. et al. Acquired von Willebrand’s disease in the myeloproliferative syndrome. Blood 1984; 64: 981-5
• 53 Greist A. The role of blood component removal in essential and reactive thrombocytosis. Ther Apher 2002; 6: 36-44
• 54 Björkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR. et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011; 29: 2410-5
• 55 Kundranda MN, Tibes R, Mesa RA. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: Does anything work?. Curr Hematol Malig Rep 2012; 7: 78-86
• 56 Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y. et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: A report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010; 116: 3735-42
• 57 Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: A meta-analysis. Blood 2012; 120: 4921-8
• 58 Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/polycythemia vera and pregnancy: The need for an observational study in Europe. Semin Thromb Hemost 2006; 32: 422-9
• 59 Harrison CN, Robinson SE. Myeloproliferative disorders in pregnancy. Hematol Oncol Clin North Am 2011; 25: 261-75, vii
• 60 Barbui T, Finazzi G. Special issues in myeloproliferative neoplasms. Curr Hematol Malig Rep 2011; 6: 28-35